September 24, 2020

The Niche

Knoepfler lab stem cell blog

3-person IVF

5 min read

An important new Cell Stem Cell paper from Dieter Egli’s lab points to an inherent, serious problem with so-called 3-person IVF or mitochondrial replacement technology that warrants putting an immediate hold on all efforts to use it in humans. I have pasted the graphical abstract from the paper below. For years a few of us scientists and policy groups have argued strongly that this experimental technology is far too risky to try in humans for reproductive efforts in the near future. There were simply not enough …Read More

23 min read

Editor’s note. Caroline Simons attended both the April 28th (see her report on that here) and 29th Paris meetings on human gene editing/genetic modification. Today, we have her in depth report on the April 29th meeting. I have posted her piece in full with only minor edits. If you are in a rush you can skip to the last page for Caroline’s top 10 takeaways from the meeting. By Caroline Simons The meeting of NAS and NAM which took place in Paris on 29 …Read More

7 min read

Editors note: This is a guest post from Caroline Simons who is attending the two Paris meetings on human gene editing. For more background on those meetings see here. By Caroline Simons There were just over a hundred participants at the workshop organized by the Federation of European Academies of Medicine, the UK Academy of Medical Sciences and the Académie Nationale de Médicine France. That number included experts in the fields of science, medicine, law and bioethics. They came from Europe, the US and …Read More

15 min read

I talked last year about human genetic modification by CRISPR with George Church a year ago. Now we’ve followed up with a long chat on this topic going into much more detail and with questions on recent developments. Each question is listed numerically and then there is a back and forth on that question with George and me before going on to the next question. Frameworks for managing human genetic modification 1. Paul: What do you think of my ABCD plan for handling human germline …Read More